C91.50
Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission
Clinical Classification Guidelines
Inclusion Terms
- Adult T-cell lymphoma/leukemia (HTLV-1-associated) with failed remission
- Adult T-cell lymphoma/leukemia (HTLV-1-associated) NOS
Medical Intelligence & Overview
Adult T-cell lymphoma/leukemia (ATLL) associated with the human T-cell lymphotropic virus type 1 (HTLV-1) is a rare but serious blood cancer. When this disease has not responded to treatment and remains active, it is classified as 'not having achieved remission.' This condition requires careful medical management and ongoing attention to symptoms and treatment options.
Causes & Symptoms
Clinical Causes: Infection with the human T-cell lymphotropic virus type 1 (HTLV-1): This virus infects certain immune cells (T-cells), which can lead to abnormal growth and cancer. Genetic factors: Certain genetic predispositions may increase the risk of developing ATLL after HTLV-1 infection. Environmental exposures: Although less common, some environmental factors may contribute to the risk, especially in regions where HTLV-1 is endemic.
Key Symptoms: Enlarged lymph nodes, often painless Persistent fever Unexplained weight loss Frequent infections due to weakened immune system Fatigue and weakness Skin lesions or rashes Abdominal discomfort or swelling Night sweats Persistent cough or shortness of breath if the lungs are affected
Diagnostic & Treatment
Diagnosis Path: Blood tests: To identify abnormal T-cells and confirm the presence of HTLV-1 infection Lymph node biopsy: Examining tissue samples to detect cancerous cells Imaging studies: CT scans, PET scans, or MRI to determine the extent of disease spread Bone marrow biopsy: To examine marrow where abnormal T-cells may be present Laboratory tests: To assess overall health and organ function
Treatment Protocols: Chemotherapy: Use of cancer-fighting drugs to kill or reduce abnormal T-cells Targeted therapy: Medications that specifically target cancer cells Antiviral treatments: Although their role is limited, these may be considered in some cases Immunotherapy: Boosting the immune system's ability to fight cancer Stem cell transplant: Replacing diseased bone marrow with healthy cells, often in eligible patients Supportive care: Managing symptoms such as pain, infections, and nutritional needs
Clinical Advice & FAQs
Billing Guidance
Is C91.50 a billable ICD-10 code?
Yes, C91.50 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C91.50?
Clinical documentation must specify the nature of Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference